Abstract
Objective:
The authors' goal was to determine whether sertraline attenuates the increased platelet activation seen among depressed patients.
Method:
They tested 21 otherwise healthy patients with untreated major depressive episode who were 25-52 years old and 21 age- and sex-matched comparison subjects. Patients received 6 weeks of sertraline treatment, and 17 returned for retesting.
Results:
At baseline, the depressed patients had greater platelet secretion than the comparison subjects in response to collagen. Depressed patients with a family history of coronary disease had nonsignificantly greater wound-induced fibrinogen receptor binding than the other subjects. Platelet secretion in response to collagen was significantly reduced after treatment with sertraline.
Conclusions:
Sertraline diminished the increased platelet secretion found among depressed patients, although the findings are limited by a lack of a placebo control group.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Blood Platelets / drug effects
-
Blood Platelets / metabolism
-
Collagen / pharmacology
-
Depressive Disorder / diagnosis
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / psychology
-
Female
-
Humans
-
Male
-
Middle Aged
-
Platelet Activation / drug effects*
-
Platelet Glycoprotein GPIIb-IIIa Complex / drug effects
-
Platelet Glycoprotein GPIIb-IIIa Complex / metabolism
-
Psychiatric Status Rating Scales / statistics & numerical data
-
Receptors, Serotonin / drug effects
-
Receptors, Serotonin / metabolism
-
Selective Serotonin Reuptake Inhibitors / pharmacology*
-
Selective Serotonin Reuptake Inhibitors / therapeutic use*
-
Sertraline / pharmacology*
-
Sertraline / therapeutic use*
-
Treatment Outcome
Substances
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Receptors, Serotonin
-
Serotonin Uptake Inhibitors
-
Collagen
-
Sertraline